Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2018

View Archived Issues

FDA accepts IND application for BIVV-003 as treatment for sickle cell disease

Eisai reviews key milestones of fourth quarter of fiscal 2017

G1 Therapeutics initiates phase I study of G1T48 in ER-positive, HER-negative advanced breast cancer

MedImmune studies MEDI-9447 combination therapies for advanced NSCLC

Bayer initiates phase II/III study of rogaratinib in FGFR-positive advanced urothelial carcinoma

SCGA gene expression seen after vector delivery in limb girdle muscular dystrophy type 2D patients

Primary endpoint met in phase III study of Lyrica oral solution CV in pediatric epilepsy

Rocket Pharmaceuticals partners with Stanford University School of Medicine on gene therapies

BeiGene initiates phase III study of pamiparib in ovarian cancer

Takeda reflects on active fourth quarter of fiscal 2017

IND-enabling studies initiated for Bicycle Therapeutics' BT-5528

Sumitomo Dainippon Pharma presents preclinical results for DSP-0692 in cancer

Profectus Biosciences and Medisun Holdings team to launch ProMed BioSciences

FDA approves Aimovig for prevention of migraine

Merck KGaA and Washington University in St. Louis to study gut microbiome for malnourishment

Pharmazz presents promising interim analysis of phase II data for PMZ-2010

Janssen discontinues development of atabecestat for late-onset preclinical stage Alzheimer's

MET inhibitor OMO-1 shows promising preclinical antitumoral activity

IDAC Theranostics and Keio University present apoptosis inducers

Qingdao Marine Biomedical Research Institute patents ROS-production inhibitors

Beijing Konruns Pharmaceutical divulges UFO and VEGFR-2 inhibitors

CRISPR Therapeutics designs new method for generating BCMA-targeted CAR-T cells

Damian Pharma discloses CYP11B2 inhibitors

Daewoong Pharmaceutical presents TNF-alpha production inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...